newsfilter
← Latest News
GlobeNewswire·

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration